Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: August 5, 2002
Last updated: May 14, 2011
Last verified: December 2009

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have myelodysplastic syndrome, acute myeloid leukemia, or non-Hodgkin's lymphoma.

Condition Intervention Phase
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Drug: romidepsin
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: May 2002
Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the pattern of adverse clinical experience in patients with myelodysplastic syndrome, acute myeloid leukemia, or intermediate-grade or follicular non-Hodgkin's lymphoma treated with FR901228 (depsipeptide).
  • Determine the disease response in patients treated with this drug.
  • Determine the pharmacokinetic and pharmacodynamic correlates of this drug, including measurement of serum plasma levels, H3 and H4 acetylation, apoptosis induction, differentiation, and multidrug-resistant (MDR) phenotype expression in these patients.

OUTLINE: Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1 and 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed monthly.

PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study within 1 year.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • One of the following diagnoses:

    • Histologically confirmed refractory or relapsed acute myeloid leukemia (AML)

      • Failed anthracycline-based chemotherapy
      • Ineligible for or refused allogeneic stem cell transplantation
    • Elderly patients with newly diagnosed AML

      • Ineligible for or refused standard chemotherapy
    • Histologically confirmed high-risk myelodysplastic syndromes

      • Eligible subtypes include:

        • Refractory anemia with excess blasts (RAEB)
        • RAEB in transformation
        • Chronic myelomonocytic leukemia
      • Ineligible for or refused allogeneic bone marrow transplantation
    • Histologically confirmed intermediate-grade non-Hodgkin's lymphoma (NHL)

      • Relapsed after high-dose therapy OR
      • Ineligible for allogeneic or autologous stem cell transplantation
      • Evaluable lesions by radiologic study or physical examination
    • Histologically confirmed follicular NHL

      • Progressed after anthracycline-based chemotherapy and rituximab
      • Evaluable lesions by radiologic study or physical examination NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.



  • 18 and over

Performance status

  • Karnofsky 60-100%

Life expectancy

  • Not specified


  • Not specified


  • Bilirubin no greater than 1.5 mg/dL (unless due to Gilbert's syndrome)
  • SGOT and SGPT less than 2 times upper limit of normal


  • Creatinine no greater than 1.5 mg/dL OR
  • Creatinine clearance at least 60 mL/min


  • Cardiac ejection fraction greater than 50%
  • No cardiac hypertrophy
  • No known conduction heart disease
  • No New York Heart Association class III or IV heart disease that would make it difficult to assess patient during study participation
  • No significant prior heart disease
  • No significant prior secondary or tertiary heart block
  • No significant prior atrial or ventricular arrhythmia requiring therapeutic intervention or antiarrhythmics for rate control


  • No severe debilitating pulmonary disease that would make it difficult to assess patient during study participation


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 1 month after study participation
  • Potassium ≥ 4.0 mmol/L (supplementation allowed)
  • Magnesium ≥ 2.0 mg/dL (supplementation allowed)
  • No other concurrent active malignancy except basal cell skin cancer
  • No other concurrent significant co-morbidity that would make it difficult to assess patient during study participation


Biologic therapy

  • See Disease Characteristics
  • At least 2 weeks since prior epoetin alfa or filgrastim (G-CSF)
  • At least 4 weeks since prior cytokines
  • No concurrent immunotherapy


  • See Disease Characteristics
  • At least 4 weeks since prior systemic chemotherapy
  • No other concurrent chemotherapy

Endocrine therapy

  • Not specified


  • At least 4 weeks since prior radiotherapy
  • No concurrent radiotherapy


  • Not specified


  • No other concurrent investigational agents
  • No concurrent drugs that may prolong the QTc interval

    • FR901228 (depsipeptide) may be administered after a 5-half-life washout period following the use of these drugs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00042822

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Study Chair: Virginia Klimek, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
Publications: Identifier: NCT00042822     History of Changes
Other Study ID Numbers: CDR0000069473, MSKCC-00116, NCI-1715
Study First Received: August 5, 2002
Last Updated: May 14, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent adult acute myeloid leukemia
refractory anemia with excess blasts
refractory anemia with excess blasts in transformation
chronic myelomonocytic leukemia
recurrent grade 3 follicular lymphoma
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
untreated adult acute myeloid leukemia
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse small cleaved cell lymphoma
atypical chronic myeloid leukemia, BCR-ABL1 negative
myelodysplastic/myeloproliferative neoplasm, unclassifiable
adult acute myeloid leukemia with t(8;21)(q22;q22)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with t(15;17)(q22;q12)

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions processed this record on November 20, 2014